Literature DB >> 27560709

Histone Deacetylase Inhibitory Approaches for the Management of Osteoarthritis.

Chandra K Singh1, Minakshi Nihal1, Nihal Ahmad2.   

Abstract

This commentary highlights the article by Makki and Haqqi that proposes the use of vorinostat as a therapeutic agent for the management of osteoarthritis.
Copyright © 2016 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27560709      PMCID： PMC5037642          DOI： 10.1016/j.ajpath.2016.08.001

Source DB:  PubMed          Journal:  Am J Pathol        ISSN： 0002-9440            Impact factor:   4.307


  22 in total

Review 1.  A current review of molecular mechanisms regarding osteoarthritis and pain.

Authors:  Andrew S Lee; Michael B Ellman; Dongyao Yan; Jeffrey S Kroin; Brian J Cole; Andre J van Wijnen; Hee-Jeong Im
Journal:  Gene       Date:  2013-07-02       Impact factor: 3.688

2.  A novel domain in histone deacetylase 1 and 2 mediates repression of cartilage-specific genes in human chondrocytes.

Authors:  Sohee Hong; Assia Derfoul; Lucilia Pereira-Mouries; David J Hall
Journal:  FASEB J       Date:  2009-06-26       Impact factor: 5.191

Review 3.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.

Authors:  Paul A Marks; Ronald Breslow
Journal:  Nat Biotechnol       Date:  2007-01       Impact factor: 54.908

4.  Alleviation of osteoarthritis by Trichostatin A, a histone deacetylase inhibitor, in experimental osteoarthritis.

Authors:  Wei-Ping Chen; Jia-Peng Bao; Peng-Fei Hu; Jie Feng; Li-Dong Wu
Journal:  Mol Biol Rep       Date:  2010-03-17       Impact factor: 2.316

5.  Vorinostat, a HDAC inhibitor, showed anti-osteoarthritic activities through inhibition of iNOS and MMP expression, p38 and ERK phosphorylation and blocking NF-κB nuclear translocation.

Authors:  Hui-ming Zhong; Qian-hai Ding; Wei-ping Chen; Ru-bin Luo
Journal:  Int Immunopharmacol       Date:  2013-07-13       Impact factor: 4.932

6.  Histone Deacetylase Inhibitor Vorinostat (SAHA) Suppresses IL-1β-Induced Matrix Metallopeptidase-13 Expression by Inhibiting IL-6 in Osteoarthritis Chondrocyte.

Authors:  Mohammad Shahidul Makki; Tariq M Haqqi
Journal:  Am J Pathol       Date:  2016-08-20       Impact factor: 4.307

7.  Increased apoptotic chondrocytes in articular cartilage from adult heterozygous SirT1 mice.

Authors:  Odile Gabay; Hanna Oppenhiemer; Hadar Meir; Kristien Zaal; Christelle Sanchez; Mona Dvir-Ginzberg
Journal:  Ann Rheum Dis       Date:  2012-01-17       Impact factor: 19.103

8.  Class I histone deacetylase inhibition modulates metalloproteinase expression and blocks cytokine-induced cartilage degradation.

Authors:  Kirsty L Culley; Wang Hui; Matt J Barter; Rose K Davidson; Tracey E Swingler; Auriane P M Destrument; Jenny L Scott; Simon T Donell; Steve Fenwick; Andrew D Rowan; David A Young; Ian M Clark
Journal:  Arthritis Rheum       Date:  2013-07

9.  Histone deacetylase 4 alters cartilage homeostasis in human osteoarthritis.

Authors:  Jingwei Lu; Ye Sun; Qiting Ge; Huajian Teng; Qing Jiang
Journal:  BMC Musculoskelet Disord       Date:  2014-12-17       Impact factor: 2.362

Review 10.  The role of dietary histone deacetylases (HDACs) inhibitors in health and disease.

Authors:  Shalome A Bassett; Matthew P G Barnett
Journal:  Nutrients       Date:  2014-10-15       Impact factor: 5.717
View more
  3 in total

Review 1.  The Role of Sirtuins in Antioxidant and Redox Signaling.

Authors:  Chandra K Singh; Gagan Chhabra; Mary Ann Ndiaye; Liz Mariely Garcia-Peterson; Nicholas J Mack; Nihal Ahmad
Journal:  Antioxid Redox Signal       Date:  2017-10-20       Impact factor: 8.401

2.  Hydrostatic Pressure Regulates MicroRNA Expression Levels in Osteoarthritic Chondrocyte Cultures via the Wnt/β-Catenin Pathway.

Authors:  Sara Cheleschi; Anna De Palma; Alessandra Pecorelli; Nicola Antonio Pascarelli; Giuseppe Valacchi; Giuseppe Belmonte; Serafino Carta; Mauro Galeazzi; Antonella Fioravanti
Journal:  Int J Mol Sci       Date:  2017-01-12       Impact factor: 5.923

3.  Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis.

Authors:  He-Ming Huang; Shi-Jie Fan; Xiao-Ru Zhou; Yan-Jun Liu; Xiao Li; Li-Ping Liao; Jing Huang; Cui-Cui Shi; Liang Yu; Rong Fu; Jian-Gao Fan; Yuan-Yuan Zhang; Cheng Luo; Guang-Ming Li
Journal:  Acta Pharmacol Sin       Date:  2021-08-02       Impact factor: 6.150
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.